1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 75, 2024
  5. Article

Annual Review of Medicine

Volume 75, 2024

Lessons Learned from Approval of Aducanumab for Alzheimer's Disease

Abstract

When the US Food and Drug Administration used the accelerated approval process to authorize the use of the antiamyloid drug aducanumab to treat Alzheimer's disease (AD), many people hoped this signaled a new era of disease-modifying treatment. But 2 years later, aducanumab's failure to launch provides a cautionary tale about the complexities of dementia and the need for a thorough and transparent review of the role that regulatory agencies and various stakeholders play in approving AD drugs. We highlight the events leading to aducanumab's controversial approval and discuss some of the key lessons learned from the drug's failure to deliver the hoped-for benefits. These lessons include the inherent limitations of antiamyloid strategies for a complex disease in which amyloid is only one of several pathological processes, the need for clinical trials that better reflect the diversity of communities affected by AD, the potential pitfalls of futility analyses in clinical trials, the need for greater transparency and other modifications to the approval process, and the dementia field's unreadiness to move from the highly controlled environment of clinical trials to the widespread and chronic use of resource-intensive, disease-modifying drugs in real-world treatment scenarios. People with dementia desperately need effective therapies. We hope that the aducanumab story will inspire changes to the approval process—changes that restore public trust and improve future efforts to deliver disease-modifying therapies to the clinic.

Keyword(s): accelerated approval, antiamyloid, clinical trials, dementia, drug approval, immunotherapy
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-051022-043645
2024-01-29
2024-05-07
Loading full text...

Full text loading...

/deliver/fulltext/med/75/1/annurev-med-051022-043645.html?itemId=/content/journals/10.1146/annurev-med-051022-043645&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Higgins-Dunn N. 2021. Biogen's shockingly broad Aduhelm label—and $56K price—set up a $10B launch, analysts say. Fierce Pharma June 7. https://www.fiercepharma.com/pharma/alzheimer-s-fda-nod-bag-biogen-faces-historic-drug-launch-and-10b-potential-sales-analysts
    [Google Scholar]
  2. 2.
    Biogen 2021. Biogen announces reduced price for ADUHELM® to improve access for patients with early Alzheimer's disease News Release, Dec. 20 Biogen, Cambridge, MA: https://investors.biogen.com/news-releases/news-release-details/biogen-announces-reduced-price-aduhelmr-improve-access-patients
  3. 3.
    US Cent. Medicare & Medicaid Serv. (CMS) 2022. Monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease Decision Summary, Decision Memo CAG-00460N, Apr. 7 US Cent. Medicare & Medicaid Serv. Baltimore, MD: https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=305
  4. 4.
    Hardy JA, Higgins GA. 1992. Alzheimer's disease: the amyloid cascade hypothesis. Science 256:5054184–85
     [Google Scholar]
  5. 5.
    Selkoe DJ. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:2741–66
     [Google Scholar]
  6. 6.
    Schenk D, Barbour R, Dunn W et al. 1999. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:6740173–77
     [Google Scholar]
  7. 7.
    Bard F, Cannon C, Barbour R et al. 2000. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:8916–19
     [Google Scholar]
  8. 8.
    Gilman S, Koller M, Black RS et al. 2005. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:9155–62
     [Google Scholar]
  9. 9.
    Salloway S, Sperling R, Fox NC et al. 2014. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370:4322–33
     [Google Scholar]
  10. 10.
    Doody RS, Thomas RG, Farlow M et al. 2014. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370:4311–21
     [Google Scholar]
  11. 11.
    Honig LS, Vellas B, Woodward M et al. 2018. Trial of solanezumab for mild dementia due to Alzheimer's disease. N. Engl. J. Med. 378:4321–30
     [Google Scholar]
  12. 12.
    Ostrowitzki S, Bittner T, Sink KM et al. 2022. Evaluating the safety and efficacy of crenezumab versus placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials. JAMA Neurol. 79:111113–21
     [Google Scholar]
  13. 13.
    Budd Haeberlein S, Aisen PS, Barkhof F et al. 2022. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J. Prev. Alzheimer's Dis. 9:2197–210
     [Google Scholar]
  14. 14.
    van Dyck CH, Swanson CJ, Aisen P et al. 2023. Lecanemab in early Alzheimer's disease. N. Engl. J. Med. 388:9–21
     [Google Scholar]
  15. 15.
    Rogers MB. 2022. Gantenerumab mystery: How did it lose potency in phase 3?. ALZFORUM Dec. 20. https://www.alzforum.org/news/conference-coverage/gantenerumab-mystery-how-did-it-lose-potency-phase-3
    [Google Scholar]
  16. 16.
    Sims JR, Zimmer JA, Evans CD et al. 2023. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330:6512–27
     [Google Scholar]
  17. 17.
    Arndt JW, Qian F, Smith BA et al. 2018. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci. Rep. 8:6412
     [Google Scholar]
  18. 18.
    Sevigny J, Chiao P, Bussière T et al. 2016. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 537:761850–56
     [Google Scholar]
  19. 19.
    Morris JC. 1993. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43:112412–14
     [Google Scholar]
  20. 20.
    Salloway S, Chalkias S, Barkhof F et al. 2022. Amyloid-related imaging abnormalities in two phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 79:113–21
     [Google Scholar]
  21. 21.
    Alexander GC, Knopman DS, Emerson SS et al. 2021. Revisiting FDA approval of aducanumab. N. Engl. J. Med. 385:9769–771
     [Google Scholar]
  22. 22.
    US Food Drug Adm. (FDA) 2021. ADUHELM highlights of prescribing information Revised June 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf
  23. 23.
    US Food Drug Adm. (FDA) 2021. ADUHELM highlights of prescribing information Revised July 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s003lbl.pdf
  24. 24.
    Belluck P, Robbins R. 2021. Three F.D.A. advisers resign over agency's approval of Alzheimer's drug. N.Y. Times June 10. https://www.nytimes.com/2021/06/10/health/aduhelm-fda-resign-alzheimers.html
    [Google Scholar]
  25. 25.
    Staffs of the Committee on Oversight and Reform and Committee on Energy and Commerce 2022. The high price of Aduhelm's approval: an investigation into FDA's atypical review process and Biogen's aggressive launch plans Rep., US House of Representatives, Dec. https://oversightdemocrats.house.gov/sites/democrats.oversight.house.gov/files/2022-12-29.COR%20%26%20E%26C%20Joint%20Staff%20Report%20re.%20Aduhelm.pdf
  26. 26.
    Synnott PG, Whittington MD, Lin GA et al. 2021. Aducanumab for Alzheimer's disease: effectiveness and value Rep., California Technology Assessment Forum, Aug. 5. Updated Jan. 17, 2023. https://icer.org/wp-content/uploads/2020/10/ICER_ALZ_Final_Report_080521-1.pdf
  27. 27.
    Muoio D. 2021. Mass General Brigham vetoes controversial Alzheimer's drug Aduhelm after internal review. Fierce Healthcare Sep. 29. https://www.fiercehealthcare.com/hospitals/mass-general-brigham-vetoes-controversial-alzheimer-s-drug-aduhelm-after-internal-review
    [Google Scholar]
  28. 28.
    Alzheimer's Assoc 2021. Change of Aduhelm price by Biogen is only a step toward equitable access to treatments for Alzheimer's disease News Release, Dec. 20 Alzheimer's Assoc. Chicago, IL: https://www.alz.org/news/2021/change-of-aduhelm-price-by-biogen-is-only-a-step-t
  29. 29.
    Silvestrini E. 2022. Medicare costs to go down in 2023. Kiplinger Oct. 12. https://www.kiplinger.com/retirement/medicare-costs-to-go-down-in-2023
    [Google Scholar]
  30. 30.
    Kim CK, Lee YR, Ong L et al. 2022. Alzheimer's disease: key insights from two decades of clinical trial failures. J. Alzheimer's Dis. 87:183–100
     [Google Scholar]
  31. 31.
    Andrews JS, Desai U, Kirson NY et al. 2019. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials. Alzheimer's Dement. 5:354–63
     [Google Scholar]
  32. 32.
    Lansdall CJ, McDougall F, Butler LM et al. 2023. Establishing clinically meaningful change on outcome assessments frequently used in trials of mild cognitive impairment due to Alzheimer's disease. . J. Prev. Alzheimer's Dis. 10:9–18
     [Google Scholar]
  33. 33.
    Karran E, De Strooper B. 2022. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat. Rev. Drug. Discov. 21:4306–18
     [Google Scholar]
  34. 34.
    Nelson PT, Alafuzoff I, Bigio EH et al. 2012. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 71:5362–81
     [Google Scholar]
  35. 35.
    Malpetti M, Joie R, Rabinovici GD 2022. Tau beats amyloid in predicting brain atrophy in Alzheimer disease: implications for prognosis and clinical trials. J. Nucl. Med. 63:6830–32
     [Google Scholar]
  36. 36.
    Haass C, Selkoe D. 2022. If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?. PLOS Biol. 20:7e3001694
     [Google Scholar]
  37. 37.
    Jiang Y, Zhou X, Wong HY et al. 2022. An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer's disease. Nat. Aging 2:7616–634
     [Google Scholar]
  38. 38.
    Eissman JM, Dumitrescu L, Mahoney ER et al. 2022. Sex differences in the genetic architecture of cognitive resilience to Alzheimer's disease. Brain 145:72541–54
     [Google Scholar]
  39. 39.
    Lopera F, Marino C, Chandrahas AS et al. 2023. Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man. Nat. Med. 29:51243–52
     [Google Scholar]
  40. 40.
    Golde TE. 2022. Disease-modifying therapies for Alzheimer's disease: more questions than answers. Neurotherapeutics 19:1209–27
     [Google Scholar]
  41. 41.
    Cummings J. 2022. Disease modification is not all—we need symptomatic therapies for Alzheimer disease. Nat. Rev. Neurol. 18:3–4
     [Google Scholar]
  42. 42.
    Gurland BJ, Wilder DE, Lantigua R et al. 1999. Rates of dementia in three ethnoracial groups. Int. J. Geriatr. Psychiatry 14:6481–93
     [Google Scholar]
  43. 43.
    Aranda MP, Kremer IN, Hinton L et al. 2021. Impact of dementia: health disparities, population trends, care interventions, and economic costs. J. Am. Geriatr. Soc. 69:71774–83
     [Google Scholar]
  44. 44.
    Portacolone E, Palmer NR, Lichtenberg P et al. 2020. Earning the trust of African American communities to increase representation in dementia research. Ethn. Dis. 30:Suppl. 2719–34
     [Google Scholar]
  45. 45.
    Shaw AR, Perales-Puchalt J, Moore T et al. 2022. Recruitment of older African Americans in Alzheimer's disease clinical trials using a community education approach. J. Prev. Alzheimer's Dis. 9:4672–78
     [Google Scholar]
  46. 46.
    Gazaway S, Bakitas M, Underwood F et al. 2023. Community informed recruitment: a promising method to enhance clinical trial participation. J. Pain Symptom. Manag. 65:6e757–64
     [Google Scholar]
  47. 47.
    Gallo P, Roychoudhury S. 2023. Challenges in implementing futility schemes, with reference to aducanumab. Ther. Innov. Regul. Sci. 57:3515–520
     [Google Scholar]
  48. 48.
    Largent EA, Karlawish J. 2020. Rescuing research participants after Alzheimer trials stop early: sending out an SOS. JAMA Neurol. 77:4413–14
     [Google Scholar]
  49. 49.
    Largent EA, Walter S, Childs N et al. 2022. Putting participants and study partners FIRST when clinical trials end early. Alzheimer's Dement. 18:122736–46
     [Google Scholar]
  50. 50.
    Kennedy B, Tyson A, Funk C. 2022. Americans value U.S. role as scientific leader, but 38% say country is losing ground globally Rep., Oct. 25 Pew Res. Cent. Sci. Soc. Washington, DC: https://www.pewresearch.org/science/2022/10/25/americans-value-u-s-role-as-scientific-leader-but-38-say-country-is-losing-ground-globally/
  51. 51.
    Karlawish J, Grill JD. 2021. The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA. Nat. Rev. Neurol. 17:9523–24
     [Google Scholar]
  52. 52.
    Maulden A. 2022. Ignoring the experts: implications of the FDA's Aduhelm approval. Am. J. Law Med. 48:1108–33
     [Google Scholar]
  53. 53.
    Largent EA, Peterson A, Karlawish J, Lynch HF. 2022. Aspiring to reasonableness in accelerated approval: anticipating and avoiding the next aducanumab. Drugs Aging 39:6389–400
     [Google Scholar]
  54. 54.
    DiStefano MJ, Alexander GC, Polsky D, Anderson GF. 2022. Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: a nationally representative survey. J. Am. Geriatr. Soc. 70:61685–94
     [Google Scholar]
  55. 55.
    Drabo EF, Barthold D, Joyce G et al. 2019. Longitudinal analysis of dementia diagnosis and specialty care among racially diverse Medicare beneficiaries. Alzheimer's Dement. 15:111402–11
     [Google Scholar]
  56. 56.
    Liu JL, Hlavka JP, Hillestad R, Mattke S. 2017. Assessing the preparedness of the U.S. health care system infrastructure for an Alzheimer's treatment Rep., RAND Corp https://www.rand.org/pubs/research_reports/RR2272.html
  57. 57.
    Hansson O, Rutz S, Zetterberg H et al. 2020. Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF. Alzheimer's Dement. 12:1e12137 Erratum 2021. Alzheimer's Dement. 13:1e12176
     [Google Scholar]
  58. 58.
    Coerver K, Yu MM, D'Abreu A et al. 2022. Practical considerations in the administration of aducanumab for the neurologist. Neurol. Clin. Pract. 12:2169–75
     [Google Scholar]
/content/journals/10.1146/annurev-med-051022-043645
Loading
Lessons Learned from Approval of Aducanumab for Alzheimer's Disease
Annual Review of Medicine 75, 99 (2024); https://doi.org/10.1146/annurev-med-051022-043645
/content/journals/10.1146/annurev-med-051022-043645
/content/journals/10.1146/annurev-med-051022-043645
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error